Exhibitors

Meet the Exhibitors at the 36th International Symposium on ALS/MND who will showcase information both on the virtual platform and in San Diego. Find out more below:

Alamar Biosciences is a pioneering life sciences company dedicated to transforming precision medicine through ultra-sensitive proteomic technologies. Founded with a mission to power precision proteomics to enable the earliest detection of disease, Alamar develops tools that allow researchers and clinicians to detect and quantify proteins at previously unreachable levels—empowering breakthroughs in early disease detection, therapeutic monitoring, and biomarker discovery.

The ALL ALS Research Consortium brings together a dedicated community of researchers, people affected by ALS, government agencies, industry leaders, and non-profits to work towards research advancements for ALS. Funded by the NIH, this nationwide initiative is gathering critical clinical data, biosamples, and digital health information from participants with ALS, genetically at risk, and healthy volunteers to accelerate research and ultimately improve the lives of those affected by this disease.

The ALS Therapy Development Institute (ALS TDI) is the world’s largest nonprofit research institute focused solely on finding effective treatments and cures for ALS. In our state-of-the-art labs, ALS TDI scientists lead drug discovery at every stage, working to advance the many therapies needed to ultimately end ALS. With efficiency and unwavering dedication to people with ALS, we relentlessly pursue an end to this disease.

Axol Bioscience is a leading provider of human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of high-performance iPSC-derived cells and the delivery of industry-leading laboratory services to advance the use of iPSC-based models in drug discovery and disease research. Axol offers scalable solutions including iPSC banking, reprogramming, gene editing, cell manufacturing, and quality control. The company is committed to closing the translational gap, developing physiologically relevant in vitro systems that improve consistency and relevance in human disease modelling and compound testing.

Corcept Therapeutics Incorporated (NASDAQ: CORT) is a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.

Evestia Clinical is a global CRO built for biotech. We specialize in neurology, and specialists in ALS areas, where complexity and urgency meet real patient need. With offices across Europe, North America, and APAC, we support trials from early-phase to pivotal, offering full-service delivery, FSP models, and platform solutions. Our teams integrate seamlessly, move quickly, and stay close to the science. Sponsors trust us for our continuity, strategic thinking, and biotech-first mindset. We’re especially focused on inclusive, patient-centric approaches because representation matters. We would love to speak with you regarding our expertise in ALS.

Ferrer and Prilenia, are committed to changing the lives of people with neurodegenerative diseases. United to accelerate innovative new therapies for patients, Ferrer brings expertise in rare neurological diseases, while Prilenia brings experience of pridopidine and neurodegenerative diseases. Ferrer is the highest-rated pharma B Corp, reinvesting ~50% of profits in social and environmental initiatives. Prilenia is driven by unwavering commitment to scientific excellence in developing transformative medicines for neurodegenerative disease.

LifeArc is a self-funded medical research organisation with one clear purpose – transforming the lives of people living with rare diseases and global health infections. We aim to deliver this by conducting and funding pioneering research, and working with partners to accelerate the translation of scientific breakthroughs into new tests, treatments and devices. Our vision is a world where people living with rare diseases and drug-resistant infections can access effective, life-changing treatments faster. Find out more about LifeArc and its work in MND/ALS at www.lifearc.org.

Neuralink

Neuro-Sys is a globally recognized preclinical neuro-focused CRO specializing in safety, efficacy, and mechanism of action studies for drug development. With deep expertise in neuroscience, pharmacology and discovery, we deliver reliable data through innovative technology and customized study design. Our team empowers clients to make informed decisions across development stages—building cohesive efficacy and safety narratives while ensuring efficiency, quality, and superior customer support.